维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="Aroney"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Early invasiveversus conservative strategies for unstable angina&non ST-elevation myocardial infarction in the stent era显示文摘	Hoenig M R Doust J A Aroney C N	2006	CochraneDatabase Syst Rev2006，17，00：	1
2	Comparison of abciximab with' high-dose' tirofiban in patients undergoing percutaneous coronary intervention 显示文摘	Gunasekara AP Walters DL Aroney CN	2006	Int J Cardiol2006，109，1：	1
3	Early and late cardiac perfora- tion by amplatzer atrial septal defect and patent fora- men ovale devices显示文摘	Ivens E Hamilton-Craig C Aroney C Aroney C Clarke A Jalali H	2009	J Am Soc Echocardiogr2009，22，10：	1
4	Platelet–monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab显示文摘	M.J. Ray D.L. Walters J.N.H. Bett J. Cameron P. Wood C.N. Aroney	2004	International Journal of Cardiology2004，，2：	1
5	Effects of atrial natriuretic peptide on myocardial contractile and diastolic function in patients with heart failure显示文摘	Semigran MJ Aroney CN Herrmann HC	1992	J Am Coll Cardiol1992，20，：	1
6	Effects of atrial natriuretic peptide on left ventricular function in hypertension显示文摘	Semigran MJ Aroney CN Herrmann HC	1994	Hypertension1994，24，：	1
7	Measurement of myocardial fractional flow reserve is a cost-effective way to identify coronary artery lesions of indeterminate severity that warrant revascularisation 显示文摘	TRIVEDI S ARONEY C N WALTERS D L	2005	Heart Lung Circ2005，14，：	1
8	Angiographic follow-up and clinical experience with the tantalum cordis stent显示文摘	Watson P S Ponde C K Aroney C N Cameron J Cannon A Dooris M Garrahy P J McEniery PT Bett JHN	1998	Cathet Cardiovasc Diagn1998，43，：	1
9	Effects of atrial natriuretic peptide on left ventricular function in hypertension显示文摘	Semigran MJ Aroney CN Herrmann HC		0，，：	1
10	行经皮冠状动脉介入的患者应用阿昔单抗和大剂量替罗非班的比较研究显示文摘Background: The TARGET study has been criticised for suboptimal platelet inhib ition with tirofiban. We aimed to compare a high-dose bolus regimen of tirofiba n(hd-tirofiban) to standard dose of abciximab for patients undergoing percutane ous coronary intervention(PCI). Methods: We assessed consecutive patients who re ceived either hd-tirofiban(25 mcg/kg bolus followed by 0.15 mcg/kg/min infusion for 18 h) or standard dose abciximab. In-hospital and 6-month outcomes were o btained in all cases. Results: Over an 18-month period, 109 patients who receiv ed hd-tirofiban were compared with 110 patients who received abciximab. Both hd -tirofiban and abciximab groups had acute coronary syndromes in 86%and 80%and diabetes in 10%and 13%respectively. Most patients had coronary stent implanta tion(96%vs. 98%). Thrombocytopenia(platelet count< 100,000) developed in 0.9% of patients receiving hd-tirofiban and 2%of patients receiving abciximab(p=0.5 66). Bleeding requiring transfusion occurred in 7.3%and 3%of patients respecti vely(p=0.118). Peri-procedural troponin rise was 0.9%in patients receiving hd -tirofiban and 5.5%in patients receiving abciximab(p=0.07). MACE(Myocardial in farction, Stroke, Revascularisation and Death) at 6 months was 23%in the hd-ti rofiban group and 20%in the abciximab group(p=0.711). The pharmaceutical costs were AUD 322 for hd-tirofiban(one ampoule) and AUD 1350 for abciximab(3 ampoule s). Conclusion: There was a small increase in bleeding requiring transfusion and a lower rate of peri-procedural troponin rise in the hd-tirofiban group howev er, the overall 6-month MACE rates were similar in both groups. There was a con siderable cost-saving with the use of hd-tirofiban. A prospective randomized t rial of hd-tirofiban vs. abciximab is warranted.	Gunasekara A.P. Walters D.L. Aroney C.N. 徐永城	2006	世界核心医学期刊文摘(心脏病学分册)2006，2，9：	1
11	Comparison of abciximab with “high-dose” tirofiban in patients undergoing percutaneous coronary intervention显示文摘	Gunasekara AP Waiters DL Aroney CN	2006	Int J Cardiol2006，109，1：	1
12	Early invasive versus conservative strategies for unstable angina and non - ST ele- vation myocardial infarction in the stent era 显示文摘	Hoenig MR Aroney CN Scott IA	2010	Cochrane Database Syst Rev2010，17，00：	1
13	Comparison of abciximab with ' high - dose' tirofiban in patients undergoing percutaneous coronary intervention 显示文摘	Gunasekara AP Waiters DL Aroney CN	2006	Int J Cardiol2006，109，1：	1
14	Upholsterers' glue associated with myocarditis, hepatitis, acute renal failure and lym- phoma 显示文摘	Knight A T Pawsey C G K Aroney R S	1991	Med J1991，154，5：	1
15	Cardiac troponin may be released by ischemia alone, without necrosis 显示文摘	Hickman PE Potter JM Aroney C	2010	Clin Chim Acta2010，411，：	1
16	Comparison of abciximab with “high-dose” tirofiban in patients undergoing percutaneous coronary intervention显示文摘	GUNASEKARA A P WALTERS D L ARONEY C N	2006	Int J Cardiol2006，109，：	1
17	Hacmolytic anaemia after cisplatin treatment显示文摘	Levi J A Aroney R S Dalley D N	1981	BMJ1981，282，：	1
18	Coronary stenting foramuscular bridge inapatient with hypertrophic obstructive cardiomyo-pathy 显示文摘	Walter D I Aroney C N Radford D J	2003	Cardiol Young2003，13，4：	1
19	Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era显示文摘	Hoenig MR Doust JA Aroney CN	2006	Coehrane Database Syst Rev2006，19，00：	1
20	Early invasive versus Conservative strategies for unstable angina & non ST-elevation myocardial infarction in the stent era显示文摘	Hoenig MR Doust JA Aroney CN	2006	Cochrane Database Syst Rev2006，3，00：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示